Pangaea Oncology, S.A. reported earnings results for the full year ended December 31, 2022. For the full year, the company reported sales was EUR 2.31 million compared to EUR 2.11 million a year ago. Net loss was EUR 2.71 million compared to EUR 0.641907 million a year ago.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
1.77 EUR | +1.14% | +4.12% | -3.80% |
May. 08 | Pangaea Oncology, S.A. Reports Earnings Results for the Full Year Ended December 31, 2023 | CI |
2023 | Pangaea Oncology, S.A. Reports Earnings Results for the Half Year Ended June 30, 2023 | CI |
EPS Revisions
Annual profits - Rate of surprise
1st Jan change | Capi. | |
---|---|---|
-3.80% | 58.34M | |
+24.74% | 47.54B | |
-0.47% | 41.96B | |
+43.96% | 41.55B | |
+25.40% | 30.36B | |
+17.96% | 27.61B | |
-4.47% | 28.7B | |
+50.73% | 14.7B | |
+42.56% | 13.51B | |
+1.46% | 12.34B |
- Stock Market
- Equities
- PANG Stock
- News Pangaea Oncology, S.A.
- Pangaea Oncology, S.A. Reports Earnings Results for the Full Year Ended December 31, 2022